Sanos
Private Company
Total funding raised: $6.2M
Overview
Founded in 2016, Sanos has established itself as a specialized, full-service CRO focused on three core therapeutic niches: musculoskeletal, neurological, and dermatological conditions. The company differentiates itself through deep therapeutic expertise, a science-led approach, and an integrated operational model that includes proprietary research clinics and digital recruitment platforms. With a track record of over 0+ clinical trials and a stated high patient retention rate, Sanos positions itself as a strategic partner for biopharma companies seeking efficient, high-quality clinical development in its areas of specialization.
Technology Platform
Integrated full-service CRO platform combining specialized therapeutic expertise (via NBCD, Neuroscios, Blueskin brands), digital patient recruitment analytics, proprietary research clinics (Sanos Clinic), eCOA solutions, end-to-end clinical trial supply (Sanos Supply), and advanced data science capabilities.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Sanos competes in the crowded CRO market, differentiating itself through deep specialization in three therapeutic areas and an integrated service model. It competes against large, full-service global CROs on expertise and personal service, and against other niche CROs on its breadth of integrated, in-house capabilities.